Personalis, Inc.(PSNL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,902 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PSNL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Personalis, Inc. (PSNL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PSNL at 11.3/100 on a 32-signal composite quality model, placing it at rank #2,902 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (5.5) and balance sheet strength (5.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Personalis, Inc. reports quarterly revenue of $22.4M, net income of $-31.7M, free cash flow of $-29.6M. Top institutional holders of PSNL by reported 13-F value include Merck, ARK Investment Management, BlackRock, based on the most recent SEC filings. PSNL trades on the Nasdaq exchange and files with the SEC under CIK 1527753. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PSNL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Personalis, Inc. directly from SEC EDGAR. Personalis, Inc.'s 13F Pro composite quality score has ranged between 10 and 33 since 2021, currently 11.3 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$22.4M
Net Income
Q2 2026
$-31.7M
Free Cash Flow
Q2 2026
$-29.6M
ROIC
Q2 2026
-57.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-17.7% YoYNet Income
+0.0% YoYOperating Income
-29.0% YoYEPS (Diluted)
+33.6% YoYTotal Assets
+23.6% YoYTotal Debt
Op. Cash Flow
-66.0% YoYFree Cash Flow
-69.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $69.6M -17.7% | $84.6M +15.2% | $73.5M +13.0% | $65.0M -23.9% | $85.5M +8.7% | $78.6M |
| Net Income | $-81.3M +0.0% | $-81.3M +24.9% | $-108.3M +4.4% | $-113.3M -73.7% | $-65.2M -58.0% | $-41.3M |
| Operating Income | $-88.1M -29.0% | $-68.3M +37.9% | $-109.9M +4.8% | $-115.5M -76.8% | $-65.4M -55.1% | $-42.1M |
| EPS (Diluted) | $-0.91 +33.6% | $-1.37 +39.1% | $-2.25 +9.3% | $-2.48 -66.4% | $-1.49 -24.2% | $-1.20 |
| Total Assets | $334.2M +23.6% | $270.3M +20.1% | $225.1M -23.1% | $292.7M -26.2% | $396.5M +62.0% | $244.8M |
| Total Debt | — | — | — | — | — | $0.00 |
| Operating Cash Flow | $-74.9M -66.0% | $-45.1M +19.7% | $-56.3M +19.9% | $-70.2M +0.8% | $-70.8M -66.1% | $-42.7M |
| Free Cash Flow | $-79.5M -69.9% | $-46.8M +30.4% | $-67.2M +44.1% | $-120.1M -46.7% | $-81.9M -78.5% | $-45.9M |
Get alerted when PSNL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Personalis, Inc. including:
Top Institutional Holders of PSNL
Merck & Co., Inc.
$188.2M14,044,943 shARK Investment Management LLC
$110.8M8,271,339 shBlackRock, Inc.
$94.9M7,082,491 shLightspeed Management Company, L.L.C.
$81.8M6,101,850 shAMERIPRISE FINANCIAL INC
$81.6M6,086,315 shDeep Track Capital, LP
$53.6M4,000,000 shabrdn plc
$50.2M3,747,290 shVANGUARD CAPITAL MANAGEMENT LLC
$40.3M3,010,150 shCasdin Capital, LLC
$34.2M2,550,000 shKENNEDY CAPITAL MANAGEMENT LLC
$31.7M2,364,282 sh
| Fund | Value | Shares |
|---|---|---|
| Merck & Co., Inc. | $188.2M | 14,044,943 |
| ARK Investment Management LLC | $110.8M | 8,271,339 |
| BlackRock, Inc. | $94.9M | 7,082,491 |
| Lightspeed Management Company, L.L.C. | $81.8M | 6,101,850 |
| AMERIPRISE FINANCIAL INC | $81.6M | 6,086,315 |
| Deep Track Capital, LP | $53.6M | 4,000,000 |
| abrdn plc | $50.2M | 3,747,290 |
| VANGUARD CAPITAL MANAGEMENT LLC | $40.3M | 3,010,150 |
| Casdin Capital, LLC | $34.2M | 2,550,000 |
| KENNEDY CAPITAL MANAGEMENT LLC | $31.7M | 2,364,282 |
Companies Similar to PSNL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Arcturus Therapeutics Holdings Inc.
ENANTA PHARMACEUTICALS INC
Nurix Therapeutics, Inc.
Alector, Inc.
Monte Rosa Therapeutics, Inc.
Entrada Therapeutics, Inc.
Taysha Gene Therapies, Inc.
Xencor Inc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PSNL on your watchlist
Track score changes the day Personalis, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PSNL a good stock to buy?
13F Pro's AI-powered analysis of Personalis, Inc. (PSNL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PSNL are available on the PSNL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PSNL is classified as a small company.
Which hedge funds own PSNL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PSNL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Personalis, Inc.'s investment landscape.